Organization
Vantage Data Designs
1 abstract
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,